MRK stock forecast, quote, news & analysis

Key Takeaways

• Merck (MRK) shares climbed approximately 12% over the past 30 days, rising from around $113.87 on June 18 to $127.50 by July 17, 2026.
• The dominant catalyst was FDA approval of Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol, marking Merck's entry into a large cardiovascular market with a convenient oral alternative to injectable therapies.
• Multiple Wall Street analysts raised price targets following the approval, with estimates now ranging from $138 to $155, and the consensus rating holding at Moderate Buy.
• Quarterly performance reflects a broader turnaround driven by pipeline diversification, strong Keytruda sales, and growing contributions from newer products including Winrevair and Capvaxive.
• Investors are monitoring upcoming Q2 2026 earnings, scheduled for early August, alongside continued pipeline data readouts and the integration of recent acquisitions.

Merck & Co. (MRK) Company Overview and Market Position

Merck & Co., Inc. is a global biopharmaceutical company headquartered in Rahway, New Jersey, engaged in the discovery, development, manufacturing, and marketing of prescription medicines, vaccines, biologic therapies, and animal health products. Its portfolio spans oncology, vaccines, infectious diseases, cardiometabolic disorders, and animal health. The company's flagship product, Keytruda (pembrolizumab), remains the world's top-selling cancer immunotherapy, generating approximately $31.7 billion in sales in 2025. Other major products include the HPV vaccine Gardasil, the pneumococcal vaccine Capvaxive, the pulmonary arterial hypertension therapy Winrevair, and the recently approved HIV treatment Idvynso. With a market capitalization of roughly $315 billion and institutional ownership of approximately 76%, Merck is one of the largest pharmaceutical companies globally and a component of the Dow Jones Industrial Average.

Merck & Co. (MRK) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Merck shares delivered a notable gain of approximately 12%, climbing from a closing price of $113.87 on June 18, 2026, to $127.50 on July 17. The rally accelerated sharply in late June and early July, with the stock breaking above its 50-day moving average of roughly $120 and its 200-day moving average near $117. The share price briefly touched a 52-week high of $131.74 during intraday trading on July 17 before settling slightly lower.

Zooming out to the quarterly picture, Merck's performance has been equally impressive. Following its Q1 2026 earnings report on April 30 — which showed a GAAP loss driven by a one-time acquisition charge but beat consensus estimates on both revenue and non-GAAP EPS — the stock steadily recovered from levels near $108 to its current range. The broader quarterly advance has been fueled by growing confidence in Merck's pipeline diversification strategy, with management guiding for full-year 2026 revenue of $65.8 billion to $67 billion and non-GAAP EPS of $5.04 to $5.16. Year-to-date, the stock has gained roughly 21%, significantly outperforming the broader pharmaceutical industry.

What Drove MRK Stock Price in the Last 30 Days

The single most significant catalyst during this period was the FDA approval of Lipfendra (enlicitide) as the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia. The announcement sent shares higher by more than 3% in a single session. Lipfendra is supported by two Phase III studies — CORALreef Lipids and CORALreef HeFH — which demonstrated LDL-C reductions of 56% and 59% versus placebo, respectively. The drug is expected to launch at a competitive list price of $315 per month, positioning it favorably against injectable PCSK9 therapies from Amgen and Novartis.

Beyond the Lipfendra approval, a wave of analyst upgrades and price target increases reinforced positive sentiment. Scotiabank raised its target to $155 with a Sector Outperform rating, Wells Fargo moved to $150 with an Overweight rating, and Guggenheim lifted its target to $145 with a Buy rating. Bank of America, BMO Capital Markets, JPMorgan, and UBS all raised their respective targets between $138 and $145. The consensus analyst rating remains Moderate Buy with an average target of approximately $133.94.

Additional tailwinds included continued oncology pipeline progress — with FDA acceptance of multiple regulatory filings for Keytruda-based combinations in bladder, breast, and renal cell cancers — and growing institutional interest. The pending acquisition of Terns Pharmaceuticals, expected to close soon with its promising chronic myeloid leukemia candidate TERN-701, also contributed to optimism about Merck's post-Keytruda growth strategy. Some speculative interest emerged around a reported takeover battle for genomics company Personalis, though this remains unconfirmed.

What Drove MRK Stock Performance Over the Last Quarter

The quarterly trend reflects a broader narrative of portfolio transformation. Merck's Q1 2026 results showed 5% year-over-year revenue growth to $16.3 billion, driven by an 8% increase in Keytruda family sales to $8 billion, a 43% surge in Welireg sales, and a 31% increase for Capvaxive. While the quarter included a substantial non-cash charge related to the Cidara Therapeutics acquisition, underlying operational performance exceeded expectations, and management raised full-year guidance.

Throughout the quarter, Merck secured multiple regulatory milestones: FDA approval of Idvynso for HIV, priority review for the antibody-drug conjugate ifinatamab deruxtecan in small-cell lung cancer, and expanded approval for Capvaxive in children and adolescents. The company also advanced key pipeline assets including sac-TMT, tulisokibart, and MK-3000. The closing of the Terns Pharmaceuticals acquisition and substantial institutional accumulation — including a $197.55 million new position from SEB Asset Management AB and a 6.4% increase from the Swiss National Bank — underscored institutional confidence in Merck's long-term diversification away from Keytruda dependence ahead of its 2028 patent expiry.

Trending AI Robots

For traders seeking to complement their own research with data-driven strategies, Tickeron's Trending AI Robots page offers a curated view of the platform's most compelling AI-powered trading bots. While Tickeron hosts hundreds of bots covering thousands of tickers across multiple asset classes and timeframes, only those with standout performance metrics and sustained relevance earn a place in this trending section. These bots employ diverse strategies — from swing trading to long-term trend following — and are designed to adapt to shifting market conditions using algorithmic signals and pattern recognition. The Trending AI Robots page serves as a practical starting point for investors who want to explore quantitative approaches without sifting through the entire catalog. Browsing the section can help identify which strategies are currently resonating with real-time market dynamics.

MRK Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the next major event for Merck is its Q2 2026 earnings report, scheduled for August 4. Analysts will focus on the initial commercial launch of Lipfendra, prescription trends for Keytruda Qlex following its permanent J-code implementation in April, and sales progression for Winrevair and Capvaxive. Guggenheim models Q2 revenue of approximately $16.25 billion and adjusted EPS of $0.28, though these estimates reflect the accounting impact of the Terns acquisition.

Pipeline catalysts loom large. Upcoming Phase III data readouts for sac-TMT, tulisokibart, and MK-3000 could materially shift the long-term growth narrative. The cardiovascular outcomes study for Lipfendra — evaluating whether the drug reduces major adverse cardiovascular events — remains a key long-term value driver. Investors should also monitor regulatory developments, including proposed changes to the Medicare Drug Price Negotiation Program, which could create headline risk for the pharmaceutical sector. The integration of Terns Pharmaceuticals and the advancement of TERN-701 in chronic myeloid leukemia represent additional milestones. With the 2028 Keytruda patent cliff drawing closer, every pipeline success and commercial launch takes on heightened importance for Merck's valuation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations